01826nas a2200397   4500000000100000008004100001260001700042653001500059653001000074653002400084653002600108653002400134653001000158653001100168653001200179653001600191653001100207653001200218653000900230653001600239653002500255653002000280100001400300700001600314700001800330700001500348700001600363700001200379700001300391245011700404300001100521490000700532050003200539520084300571022001401414       1992                            d  c1992 Oct-Dec10aAdolescent10aAdult10aAgglutination Tests10aAntibodies, Bacterial10aAntigens, Bacterial10aChild10aFemale10aGelatin10aGlycolipids10aHumans10aleprosy10aMale10aMiddle Aged10aMycobacterium leprae10aSerologic Tests1 aReddy B S1 aBadrinath S1 aShantaraman R1 aHarish B N1 aSheriff M O1 aRao R S1 aGarg B R00aUtility of gelatin particle agglutination test (MLPA) for rapid serodiagnosis of leprosy in a hyperendemic area.  a469-730 v64  aInfolep Library - available3 a<p>The anti-PGL M. leprae specific antibodies were estimated by MLPA test in 79 patients of leprosy, 8 contacts of lepromatous cases and 10 healthy controls in a hyperendemic area. The results indicated an over all seropositivity of 50.6% in leprosy patients. Three of the eight contacts and five of the controls also gave positive results. Higher seropositivity rates were noted in multibacillary patients (73% in lepromatous, 53.6% in borderline, 40% each in tuberculoid and indeterminate and 10% in pure neuritic types). The practical application of MLPA test in its present form as a serodiagnostic procedure for screening subclinical or clinical infections in leprosy patients appear to be of limited value in hyperendemic areas. Further studies involving large series of subjects are necessary for reaching definite conclusions.</p>  a0254-9395